Table 3. Lipids and hs-CRP.
| Characteristic | PROSPECTIVE | IMPACT | ||||||
|---|---|---|---|---|---|---|---|---|
| Control | Probucol | Control | Probucol | |||||
| N | mean±SD or median (IQR) | N | mean±SD or median (IQR) | N | mean±SD or median (IQR) | N | mean±SD or median (IQR) | |
| TC (mg/dL) | ||||||||
| Baseline | 431 | 169.5±28.7 | 400 | 169.0±28.6 | 102 | 151.3±30.7 | 92 | 151.4±34.7 |
| 3 months | 407 | 168.8±28.9 | 382 | 145.8±32.5 | 102 | 157.2±37.1 | 91 | 127.2±39.6 |
| 3 years | 343 | 167.9±29.6 | 314 | 139.8±28.9 | 97 | 154.5±39.3 | 85 | 133.8±41.2 |
| LDL-C (mg/dL) | ||||||||
| Baseline | 431 | 90.4±23.5 | 400 | 89.6±22.7 | 99 | 75.2±25.7 | 90 | 77.2±30.0 |
| 3 months | 406 | 89.3±23.2 | 375 | 81.8±23.9 | 100 | 82.4±32.1 | 88 | 69.7±33.3 |
| 3 years | 340 | 88.1±23.9 | 310 | 79.6±24.5 | 96 | 80.0±36.5 | 83 | 74.6±32.4 |
| HDL-C (mg/dL) | ||||||||
| Baseline | 431 | 54.4±14.4 | 400 | 53.6±13.6 | 102 | 46.6±12.4 | 92 | 46.4±11.8 |
| 3 months | 416 | 54.9±14.4 | 386 | 39.4±13.5 | 100 | 46.5±11.1 | 90 | 32.8±10.6 |
| 3 years | 353 | 54.8±14.1 | 317 | 37.3±12.7 | 97 | 47.6±13.3 | 85 | 35.0±14.3 |
| TG | ||||||||
| Baseline | 431 | 107 (80-154) | 400 | 114 (83-158) | 102 | 129 (92-185) | 92 | 116 (83-165) |
| 3 months | 415 | 112 (78-157) | 387 | 103 (74-150) | 102 | 128 (97-163) | 91 | 106 (73-156) |
| 3 years | 353 | 111 (76-154) | 317 | 98 (73-142) | 97 | 113 (96-166) | 84 | 107 (74-150) |
| hs-CRP | ||||||||
| Baseline | 69 | 570 (216-1640) | 56 | 698 (409-1585) | 102 | 685 (300-1160) | 92 | 665 (270-2145) |
| 3 months | 62 | 447 (229-1220) | 44 | 771 (370-1960) | 100 | 685 (360-1305) | 92 | 880 (470-1880) |
| 3 years | 39 | 478 (250-1400) | 31 | 683 (474-1680) | 97 | 890 (360-2200) | 85 | 1060 (560-2160) |
| Characteristic | PROSPECTIVE+IMPACT | |||||||
| Control | Probucol | P value† | ||||||
| N | mean±SD or median (IQR) | N | mean±SD or median (IQR) | |||||
| TC (mg/dL) | ||||||||
| Baseline | 533 | 166.0±29.9 | 492 | 165.7±30.6 | 0.694 | |||
| 3 months | 509 | 166.4±31.0 | 473 | 142.2±34.7 | ＜0.001＊ | |||
| 3 years | 440 | 164.9±32.4 | 399 | 138.6±31.9 | ＜0.001＊ | |||
| LDL-C (mg/dL) | ||||||||
| Baseline | 530 | 87.6±24.7 | 490 | 87.3±24.7 | 0.724 | |||
| 3 months | 506 | 88.0±25.3 | 463 | 79.5±26.3 | ＜0.001＊ | |||
| 3 years | 436 | 86.3±27.4 | 393 | 78.5±26.4 | ＜0.001＊ | |||
| HDL-C (mg/dL) | ||||||||
| Baseline | 533 | 52.9±14.4 | 492 | 52.3±13.6 | 0.588 | |||
| 3 months | 516 | 53.3±14.2 | 476 | 38.1±13.2 | ＜0.001＊ | |||
| 3 years | 450 | 53.2±14.2 | 402 | 36.9±13.1 | ＜0.001＊ | |||
| TG | ||||||||
| Baseline | 533 | 113 (83-157) | 492 | 114 (83-158) | 0.753 | |||
| 3 months | 517 | 114 (81-158) | 478 | 104 (74-151) | 0.010＊ | |||
| 3 years | 450 | 112 (80-160) | 401 | 101 (73-143) | 0.005＊ | |||
| hs-CRP | ||||||||
| Baseline | 171 | 660 (254-1360) | 148 | 669 (327-1720) | 0.220 | |||
| 3 months | 162 | 555 (280-1280) | 136 | 870 (440-1880) | 0.003＊ | |||
| 3 years | 136 | 666 (320-1585) | 116 | 930 (480-2110) | 0.046＊ | |||
†: Two-sample Wilcoxon test was used to evaluate the significance of differences between groups.
＊: The level of significance was set at p＜0.05 (2-sided).
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; hs-CRP, high- sensitivity C-reactive protein